Bannayan-Riley-Ruvalcaba syndrome screening: Difference between revisions

Latest revision as of 19:06, 22 March 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

There is insufficient evidence to recommend routine screening for Bannayan-Riley-Ruvalcaba syndrome (BRRS).

There is insufficient evidence to recommend routine screening for Bannayan-Riley-Ruvalcaba syndrome (BRRS).

@@ Line 4: / Line 4: @@
 {{CMG}}; {{AE}} {{VKG}}
 ==Overview==
+There is insufficient evidence to recommend routine [[Screening (medicine)|screening]] for [[Bannayan-Riley-Ruvalcaba syndrome]] (BRRS).
-There is insufficient evidence to recommend routine screening for [disease/malignancy].
-OR
-According to the [guideline name], screening for [disease name] is not recommended.
-OR
-According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
 ==Screening==
-There is insufficient evidence to recommend routine screening for [disease/malignancy].
+There is insufficient evidence to recommend routine [[Screening (medicine)|screening]] for [[Bannayan-Riley-Ruvalcaba syndrome]] (BRRS).
-OR
-According to the [guideline name], screening for [disease name] is not recommended.
-OR
-According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with:
-*[Condition 1]
-*[Condition 2]
-*[Condition 3]
 ==References==